Loading...

JUBLPHARMA Jubilant Pharmova Ltd Restructuring and reorganisations Announcement

Jbln

JBLP

Jubilant Pharmova Ltd

(JUBLPHARMA)

2025 Announcement

Results publication

Earnings call recording

FY26 results and dividend

CFO Appointment

MD & JMD appointment

CFO Appointment

Final dividend declaration

Final Dividend Declaration

Audited financial results

Audited financial results

Investor Meeting

Investor Meeting

Earnings Webinar

Analyst / Investor Meet

Board meeting intimation

Regulatory Compliance

IEPF Transfer of Shares

Trading window closure

Shareholder Notice

USFDA Inspection

Newspaper publication of re...

Earnings Update

Unaudited financial results

Unaudited Financial Results

Investor Meeting

Investor Meeting

Regulatory Compliance

Regulatory update

Regulatory Compliance

Initial investment

Trading Window Closure

Regulatory Compliance

GST Adjudication

Regulatory Update

Regulatory Compliance

USFDA Communication

Financial Results Published

Q2 FY26 Results

Stock Options Granted

Financial Results Release

Board Meeting Outcome

KYC Update Required

Board Meeting Notice

New Production Line

Unpaid Dividends Notice

Compliance Certificate

Equity Shares Transfer

Newspaper Publication

OCRPS Allotment

CFO Appointment

FDA Inspection Complete

Shareholder Reminder

GST Refund Orders

API Business Sale

Management Change

Director Resignation

Investor Meeting

Shareholder Notice

47th AGM Notice

Annual Report Dispatch

TDS on Dividend

Share Transfer Notice

Annual General Meeting

FDA Inspection Complete

Share Transfer Notice

Newspaper Publication

Investor Meeting

Financial Results Published

Management Change

CFO Resignation

Q1 FY26 Results

Stock Options Granted

Management Change

Renewable Energy Investment

Compliance Certificate

Postal Ballot Notice

Investor Meeting

API Business Sale

Tax Rectification Order

Annual Compliance Report

Financial Results Published

Q4 FY25 Results

Management Change

Credit Rating Affirmed

Chairman Update

Compliance Certificate

Trust Deed Update

Shareholders' Agreement

FDA Inspection Report

Audio Recording Available

Investor Meet Today

Investor Meeting

Financial Results Published

Q3 FY25 Results

Subsidiary Acquisition

Investor Meeting Notice

Loan Prepayment

USFDA Inspection Update

Compliance Certificate

Credit Rating Update

Meeting Deferment

Financial Results Published

Q2 FY25 Results

Loan Prepayment

Investor Meeting

Tax Demand Deletion

Compliance Certificate

Acquisition Update

Management Changes

Stock Options Granted

USFDA Inspection Update

USFDA Audit Success

Investor Meeting Scheduled

FDA Inspection Update

Investor Meeting Announced

Equity Acquisition

AGM Notice and Dividend

AGM Announcement

Management Change

Newspaper Publication

Financial Results Publication

USFDA Inspection

Financial Results Announcement

Stock Options Approval

Certificate Submission

Loan Prepayment

Advertisement Publication

USFDA Audit Completion

Radiopharmacy Expansion Inv...

Prepayment of Loan

Investor Meeting

USFDA Audit Completion

Acquisition Completion

Investment Disposal Update

Resignation Letter

Compliance Report Submission

Financial Results Publication

Financial Performance Release

Directorate Change

Newspaper Publication

Investment Announcement

Tax Relief Announcement

USFDA Audit Completion

Closure of Operations

USFDA Communication

Compliance Certificate

Certificate Confirmation

Compliance Certificate Anno...

Tax Demand Dispute

Acquisition Update

New Directors Appointed

Appointment of Directors

Credit Rating Update

Investor Meeting

Investor Meeting

Financial Results Submission

Completion of USFDA Audit

Financial Results

Management Re-Appointment

Divestment of Assets

Disposal of Investment

Confirmation Certificate Su...

Acquisition of Stake in O2 ...

FDA approval for Technetium...

Compliance Under Regulation...

Submission of Financial Res...

Financial Results

Director Resignation and Ap...

Certificate Submission

Appointment of Statutory Au...

Re-appointment of Independe...

Ongoing Litigations

Equity, Debt, VC, Private E...

Financial Statements

Postal Ballot Completion

Financial Statements

Financial Statements

Financial Statements

Equity Offerings

Resignation; Board Changes

Management Change

Appointment and Resignation

Investor Meetings

Disclosure of Related Party...

Management Changes

Financial Results

External Links:

Data:

Jubilant Pharmova Ltd has approved the sale of its Active Pharmaceutical Ingredients (API) business to its wholly-owned subsidiary, Jubilant Biosys Limited, for a consideration based on asset book value, with a turnover of Rs. 609 crores (8.35% of total revenue) and net worth of Rs. 666.5 crores (10.68% of total net worth) for the last fiscal year, effective June 12, 2025, and expected to finalize by September 1, 2025.

AI Assistant

Jubilant Pharmova Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.